Clinical Trial

Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 17, 2025 (before its estimated December 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study was to compare the study drug KN060 to enoxaparin, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-12-12; most recent amendment 2025-09-16.
Status change: Recruiting → Active, Not Recruiting 2025-09-16
Trial Details
NCT Number NCT06180889
Lead Sponsor Suzhou Alphamab Co., Ltd.
Conditions Knee Arthroplasty, Total
Enrollment 241 participants
Start Date 2023-12-20
Primary Completion 2025-12-15 (estimated)
Study Completion 2026-04-15 (estimated)
Updated on ClinicalTrials.gov 2025-09-17